ID   MRCKB_HUMAN             Reviewed;        1711 AA.
AC   Q9Y5S2; A9JR72; Q2L7A5; Q86TJ1; Q9ULU5;
DT   08-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   04-APR-2006, sequence version 2.
DT   12-OCT-2022, entry version 197.
DE   RecName: Full=Serine/threonine-protein kinase MRCK beta;
DE            EC=2.7.11.1;
DE   AltName: Full=CDC42-binding protein kinase beta;
DE            Short=CDC42BP-beta;
DE   AltName: Full=DMPK-like beta;
DE   AltName: Full=Myotonic dystrophy kinase-related CDC42-binding kinase beta;
DE            Short=MRCK beta;
DE            Short=Myotonic dystrophy protein kinase-like beta;
GN   Name=CDC42BPB {ECO:0000312|EMBL:AAD37506.1};
GN   Synonyms=KIAA1124 {ECO:0000312|EMBL:BAA86438.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAD37506.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Brain {ECO:0000312|EMBL:AAD37506.1};
RX   PubMed=10198171; DOI=10.1006/geno.1999.5769;
RA   Moncrieff C.L., Bailey M.E., Morrison N., Johnson K.J.;
RT   "Cloning and chromosomal localization of human Cdc42-binding protein kinase
RT   beta.";
RL   Genomics 57:297-300(1999).
RN   [2] {ECO:0000312|EMBL:BAA86438.2}
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-1203.
RC   TISSUE=Brain {ECO:0000312|EMBL:BAA86438.2};
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis from
RT   size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [3] {ECO:0000305}
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-1077.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000305, ECO:0000312|EMBL:AAH47871.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-1203.
RC   TISSUE=PNS {ECO:0000312|EMBL:AAH47871.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH LURAP1
RP   AND MYO18A.
RX   PubMed=18854160; DOI=10.1016/j.cell.2008.09.018;
RA   Tan I., Yong J., Dong J.M., Lim L., Leung T.;
RT   "A tripartite complex containing MRCK modulates lamellar actomyosin
RT   retrograde flow.";
RL   Cell 135:123-136(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21240187; DOI=10.1038/emboj.2010.353;
RA   Huo L., Wen W., Wang R., Kam C., Xia J., Feng W., Zhang M.;
RT   "Cdc42-dependent formation of the ZO-1/MRCKbeta complex at the leading edge
RT   controls cell migration.";
RL   EMBO J. 30:665-678(2011).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF PPP1R12A AND MYL9/MLC2, AND ACTIVITY
RP   REGULATION.
RX   PubMed=21457715; DOI=10.1016/j.febslet.2011.03.054;
RA   Tan I., Lai J., Yong J., Li S.F., Leung T.;
RT   "Chelerythrine perturbs lamellar actomyosin filaments by selective
RT   inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase.";
RL   FEBS Lett. 585:1260-1268(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690 AND SER-1693, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-423; SER-1680; SER-1682 AND
RP   SER-1686, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-671, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [19]
RP   INTERACTION WITH STRP1; STRN3 AND SIKE1.
RX   PubMed=25743393; DOI=10.1038/ncomms7449;
RA   Lant B., Yu B., Goudreault M., Holmyard D., Knight J.D., Xu P., Zhao L.,
RA   Chin K., Wallace E., Zhen M., Gingras A.C., Derry W.B.;
RT   "CCM-3/STRIPAK promotes seamless tube extension through endocytic
RT   recycling.";
RL   Nat. Commun. 6:6449-6449(2015).
RN   [20]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=29162624; DOI=10.1083/jcb.201703044;
RA   Gagliardi P.A., Somale D., Puliafito A., Chiaverina G., di Blasio L.,
RA   Oneto M., Bianchini P., Bussolino F., Primo L.;
RT   "MRCKalpha is activated by caspase cleavage to assemble an apical actin
RT   ring for epithelial cell extrusion.";
RL   J. Cell Biol. 217:231-249(2018).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 2-417 IN COMPLEXES WITH FASUDIL
RP   AND TPCA-1, FUNCTION, SUBUNIT, AND CATALYTIC ACTIVITY.
RX   PubMed=21949762; DOI=10.1371/journal.pone.0024825;
RA   Heikkila T., Wheatley E., Crighton D., Schroder E., Boakes A., Kaye S.J.,
RA   Mezna M., Pang L., Rushbrooke M., Turnbull A., Olson M.F.;
RT   "Co-crystal structures of inhibitors with MRCKbeta, a key regulator of
RT   tumor cell invasion.";
RL   PLoS ONE 6:E24825-E24825(2011).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-500; GLN-555; GLN-671; TRP-876;
RP   LYS-1315 AND TYR-1633.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase which is an important
CC       downstream effector of CDC42 and plays a role in the regulation of
CC       cytoskeleton reorganization and cell migration. Regulates actin
CC       cytoskeletal reorganization via phosphorylation of PPP1R12C and
CC       MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A
CC       and LURAP1, is involved in modulating lamellar actomyosin retrograde
CC       flow that is crucial to cell protrusion and migration
CC       (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In
CC       concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the
CC       lamellipodium resulting in its activation and subsequent
CC       phosphorylation of CFL1 which is important for lamellipodial F-actin
CC       regulation (By similarity). {ECO:0000250|UniProtKB:Q7TT50,
CC       ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21457715,
CC       ECO:0000269|PubMed:21949762}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:21949762};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000250|UniProtKB:Q5VT25,
CC         ECO:0000269|PubMed:21949762};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q5VT25};
CC   -!- ACTIVITY REGULATION: Maintained in an inactive, closed conformation by
CC       an interaction between the kinase domain and the negative
CC       autoregulatory C-terminal coiled-coil region. Agonist binding to the
CC       phorbol ester binding site disrupts this, releasing the kinase domain
CC       to allow N-terminus-mediated dimerization and kinase activation by
CC       transautophosphorylation (By similarity). Inhibited by chelerythrine
CC       chloride. {ECO:0000250, ECO:0000269|PubMed:21457715}.
CC   -!- SUBUNIT: Homodimer and homotetramer via the coiled coil regions
CC       (PubMed:21949762). Interacts tightly with GTP-bound but not GDP-bound
CC       CDC42. Interacts with TJP1, when in the presence of catalytically
CC       active CDC42 (By similarity). Forms a tripartite complex with MYO18A
CC       and LURAP1 with the latter acting as an adapter connecting CDC42BPB and
CC       MYO18A. LURAP1 binding results in activation of CDC42BPB by abolition
CC       of its negative autoregulation (PubMed:18854160). Interacts with
CC       STRIP1, STRN3 and SIKE1 (PubMed:25743393). Interacts with CPNE4 (via
CC       VWFA domain). Interacts with LURAP1. Interacts (via AGC-kinase C-
CC       terminal domain) with FAM89B/LRAP25 (via LRR repeat). Forms a
CC       tripartite complex with FAM89B/LRAP25 and LIMK1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q7TT49, ECO:0000250|UniProtKB:Q7TT50,
CC       ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21949762,
CC       ECO:0000269|PubMed:25743393}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane
CC       {ECO:0000269|PubMed:21240187}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:21240187}; Cytoplasmic side
CC       {ECO:0000269|PubMed:21240187}. Cell junction
CC       {ECO:0000269|PubMed:21240187}. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:Q3UU96}. Note=Displays a dispersed punctate
CC       distribution and concentrates along the cell periphery, especially at
CC       the leading edge and cell-cell junction. This concentration is PH-
CC       domain dependent (By similarity). Detected at the leading edge of
CC       migrating cells. Localization at the leading edge of migrating cells
CC       requires interaction with catalytically active CDC42 (PubMed:21240187).
CC       Localizes in the lamellipodium in a FAM89B/LRAP25-dependent manner (By
CC       similarity). {ECO:0000250|UniProtKB:O54874,
CC       ECO:0000250|UniProtKB:Q3UU96, ECO:0000269|PubMed:21240187}.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined, with high levels
CC       in heart, brain, placenta and lung. {ECO:0000269|PubMed:10198171}.
CC   -!- PTM: Proteolytically cleaved by caspases upon apoptosis induction.
CC       {ECO:0000269|PubMed:29162624}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. DMPK subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH47871.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAA86438.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdc42bpb/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF128625; AAD37506.1; -; mRNA.
DR   EMBL; AB032950; BAA86438.2; ALT_INIT; mRNA.
DR   EMBL; DQ355971; ABC67469.1; -; Genomic_DNA.
DR   EMBL; BC047871; AAH47871.1; ALT_SEQ; mRNA.
DR   EMBL; BC155541; AAI55542.1; -; mRNA.
DR   CCDS; CCDS9978.1; -.
DR   RefSeq; NP_006026.3; NM_006035.3.
DR   PDB; 3QFV; X-ray; 2.65 A; A/B=1-415.
DR   PDB; 3TKU; X-ray; 2.15 A; A/B=2-417.
DR   PDB; 4UAK; X-ray; 1.73 A; A=2-417.
DR   PDB; 4UAL; X-ray; 1.71 A; A=2-417.
DR   PDB; 5OTE; X-ray; 1.68 A; A=2-417.
DR   PDB; 5OTF; X-ray; 2.00 A; A=2-417.
DR   PDBsum; 3QFV; -.
DR   PDBsum; 3TKU; -.
DR   PDBsum; 4UAK; -.
DR   PDBsum; 4UAL; -.
DR   PDBsum; 5OTE; -.
DR   PDBsum; 5OTF; -.
DR   AlphaFoldDB; Q9Y5S2; -.
DR   SMR; Q9Y5S2; -.
DR   BioGRID; 114947; 92.
DR   IntAct; Q9Y5S2; 27.
DR   MINT; Q9Y5S2; -.
DR   STRING; 9606.ENSP00000355237; -.
DR   BindingDB; Q9Y5S2; -.
DR   ChEMBL; CHEMBL5052; -.
DR   DrugCentral; Q9Y5S2; -.
DR   iPTMnet; Q9Y5S2; -.
DR   MetOSite; Q9Y5S2; -.
DR   PhosphoSitePlus; Q9Y5S2; -.
DR   BioMuta; CDC42BPB; -.
DR   DMDM; 92090617; -.
DR   EPD; Q9Y5S2; -.
DR   jPOST; Q9Y5S2; -.
DR   MassIVE; Q9Y5S2; -.
DR   MaxQB; Q9Y5S2; -.
DR   PaxDb; Q9Y5S2; -.
DR   PeptideAtlas; Q9Y5S2; -.
DR   PRIDE; Q9Y5S2; -.
DR   ProteomicsDB; 86490; -.
DR   Antibodypedia; 14692; 178 antibodies from 27 providers.
DR   DNASU; 9578; -.
DR   Ensembl; ENST00000361246.7; ENSP00000355237.2; ENSG00000198752.11.
DR   GeneID; 9578; -.
DR   KEGG; hsa:9578; -.
DR   MANE-Select; ENST00000361246.7; ENSP00000355237.2; NM_006035.4; NP_006026.3.
DR   UCSC; uc001ymi.2; human.
DR   CTD; 9578; -.
DR   DisGeNET; 9578; -.
DR   GeneCards; CDC42BPB; -.
DR   HGNC; HGNC:1738; CDC42BPB.
DR   HPA; ENSG00000198752; Low tissue specificity.
DR   MIM; 614062; gene.
DR   neXtProt; NX_Q9Y5S2; -.
DR   OpenTargets; ENSG00000198752; -.
DR   PharmGKB; PA26268; -.
DR   VEuPathDB; HostDB:ENSG00000198752; -.
DR   eggNOG; KOG0612; Eukaryota.
DR   GeneTree; ENSGT01030000234517; -.
DR   HOGENOM; CLU_000288_140_3_1; -.
DR   InParanoid; Q9Y5S2; -.
DR   OMA; CGRSHHV; -.
DR   OrthoDB; 759391at2759; -.
DR   PhylomeDB; Q9Y5S2; -.
DR   TreeFam; TF313551; -.
DR   PathwayCommons; Q9Y5S2; -.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013406; RHOQ GTPase cycle.
DR   Reactome; R-HSA-9013409; RHOJ GTPase cycle.
DR   SignaLink; Q9Y5S2; -.
DR   SIGNOR; Q9Y5S2; -.
DR   BioGRID-ORCS; 9578; 12 hits in 1111 CRISPR screens.
DR   ChiTaRS; CDC42BPB; human.
DR   GenomeRNAi; 9578; -.
DR   Pharos; Q9Y5S2; Tchem.
DR   PRO; PR:Q9Y5S2; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q9Y5S2; protein.
DR   Bgee; ENSG00000198752; Expressed in stromal cell of endometrium and 184 other tissues.
DR   ExpressionAtlas; Q9Y5S2; baseline and differential.
DR   Genevisible; Q9Y5S2; HS.
DR   GO; GO:0042641; C:actomyosin; IDA:UniProtKB.
DR   GO; GO:0031252; C:cell leading edge; ISS:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IEA:Ensembl.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0031032; P:actomyosin structure organization; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0007163; P:establishment or maintenance of cell polarity; TAS:ProtInc.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd00029; C1; 1.
DR   CDD; cd05624; STKc_MRCK_beta; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR001180; CNH_dom.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR031597; KELK.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033232; MRCK_beta.
DR   InterPro; IPR042718; MRCKB_STKc.
DR   InterPro; IPR014930; Myotonic_dystrophy_kinase_coil.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22988:SF34; PTHR22988:SF34; 1.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00780; CNH; 1.
DR   Pfam; PF08826; DMPK_coil; 1.
DR   Pfam; PF15796; KELK; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00036; CNH; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50219; CNH; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell junction; Cell membrane; Cell projection;
KW   Coiled coil; Cytoplasm; Kinase; Magnesium; Membrane; Metal-binding;
KW   Methylation; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..1711
FT                   /note="Serine/threonine-protein kinase MRCK beta"
FT                   /id="PRO_0000086394"
FT   DOMAIN          76..342
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          343..413
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          1095..1214
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          1240..1513
FT                   /note="CNH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00795"
FT   DOMAIN          1583..1596
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   ZN_FING         1025..1075
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          461..484
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          969..1009
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1611..1711
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          431..815
FT                   /evidence="ECO:0000255"
FT   COILED          878..939
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        461..478
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        969..993
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1628..1657
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1660..1674
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        200
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P54265,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         82..90
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P54265,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         105
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         221
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         233
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         239
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         423
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         671
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         954
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7TT50"
FT   MOD_RES         1680
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1682
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1686
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1690
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1693
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   VARIANT         500
FT                   /note="K -> E (in a breast infiltrating ductal carcinoma
FT                   sample; somatic mutation; dbSNP:rs1158962067)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040834"
FT   VARIANT         555
FT                   /note="R -> Q (in dbSNP:rs36001612)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040835"
FT   VARIANT         671
FT                   /note="R -> Q (in dbSNP:rs55948035)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040836"
FT   VARIANT         876
FT                   /note="R -> W (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs1595472741)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040837"
FT   VARIANT         1077
FT                   /note="I -> V (in dbSNP:rs34822377)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_025847"
FT   VARIANT         1203
FT                   /note="R -> K (in dbSNP:rs146298297)"
FT                   /evidence="ECO:0000269|PubMed:10574461,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_070886"
FT   VARIANT         1315
FT                   /note="E -> K (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040838"
FT   VARIANT         1633
FT                   /note="S -> Y (in dbSNP:rs56412851)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040839"
FT   CONFLICT        1017
FT                   /note="A -> V (in Ref. 1; AAD37506)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1123
FT                   /note="D -> E (in Ref. 1; AAD37506)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..20
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          21..23
FT                   /evidence="ECO:0007829|PDB:3QFV"
FT   HELIX           27..41
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           44..47
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           50..69
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           73..75
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          76..84
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          86..95
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          101..108
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           109..114
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   TURN            115..118
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           121..130
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   TURN            133..135
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          139..144
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          146..153
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           161..167
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   TURN            168..170
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           174..193
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           203..205
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          206..208
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          214..216
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          223..225
FT                   /evidence="ECO:0007829|PDB:5OTF"
FT   STRAND          227..229
FT                   /evidence="ECO:0007829|PDB:3QFV"
FT   STRAND          231..235
FT                   /evidence="ECO:0007829|PDB:3TKU"
FT   HELIX           240..242
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           245..250
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          255..258
FT                   /evidence="ECO:0007829|PDB:3TKU"
FT   HELIX           261..276
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           286..294
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           296..299
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           311..318
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           324..326
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          330..333
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           334..337
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           340..342
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   TURN            347..349
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          362..365
FT                   /evidence="ECO:0007829|PDB:4UAK"
FT   HELIX           396..398
FT                   /evidence="ECO:0007829|PDB:5OTE"
FT   STRAND          403..406
FT                   /evidence="ECO:0007829|PDB:3QFV"
FT   STRAND          408..412
FT                   /evidence="ECO:0007829|PDB:3QFV"
SQ   SEQUENCE   1711 AA;  194315 MW;  041A009E0273ABE0 CRC64;
     MSAKVRLKKL EQLLLDGPWR NESALSVETL LDVLVCLYTE CSHSALRRDK YVAEFLEWAK
     PFTQLVKEMQ LHREDFEIIK VIGRGAFGEV AVVKMKNTER IYAMKILNKW EMLKRAETAC
     FREERDVLVN GDCQWITALH YAFQDENHLY LVMDYYVGGD LLTLLSKFED KLPEDMARFY
     IGEMVLAIDS IHQLHYVHRD IKPDNVLLDV NGHIRLADFG SCLKMNDDGT VQSSVAVGTP
     DYISPEILQA MEDGMGKYGP ECDWWSLGVC MYEMLYGETP FYAESLVETY GKIMNHEERF
     QFPSHVTDVS EEAKDLIQRL ICSRERRLGQ NGIEDFKKHA FFEGLNWENI RNLEAPYIPD
     VSSPSDTSNF DVDDDVLRNT EILPPGSHTG FSGLHLPFIG FTFTTESCFS DRGSLKSIMQ
     SNTLTKDEDV QRDLEHSLQM EAYERRIRRL EQEKLELSRK LQESTQTVQS LHGSSRALSN
     SNRDKEIKKL NEEIERLKNK IADSNRLERQ LEDTVALRQE REDSTQRLRG LEKQHRVVRQ
     EKEELHKQLV EASERLKSQA KELKDAHQQR KLALQEFSEL NERMAELRAQ KQKVSRQLRD
     KEEEMEVATQ KVDAMRQEMR RAEKLRKELE AQLDDAVAEA SKERKLREHS ENFCKQMESE
     LEALKVKQGG RGAGATLEHQ QEISKIKSEL EKKVLFYEEE LVRREASHVL EVKNVKKEVH
     DSESHQLALQ KEILMLKDKL EKSKRERHNE MEEAVGTIKD KYERERAMLF DENKKLTAEN
     EKLCSFVDKL TAQNRQLEDE LQDLAAKKES VAHWEAQIAE IIQWVSDEKD ARGYLQALAS
     KMTEELEALR SSSLGSRTLD PLWKVRRSQK LDMSARLELQ SALEAEIRAK QLVQEELRKV
     KDANLTLESK LKDSEAKNRE LLEEMEILKK KMEEKFRADT GLKLPDFQDS IFEYFNTAPL
     AHDLTFRTSS ASEQETQAPK PEASPSMSVA ASEQQEDMAR PPQRPSAVPL PTTQALALAG
     PKPKAHQFSI KSFSSPTQCS HCTSLMVGLI RQGYACEVCS FACHVSCKDG APQVCPIPPE
     QSKRPLGVDV QRGIGTAYKG HVKVPKPTGV KKGWQRAYAV VCDCKLFLYD LPEGKSTQPG
     VIASQVLDLR DDEFSVSSVL ASDVIHATRR DIPCIFRVTA SLLGAPSKTS SLLILTENEN
     EKRKWVGILE GLQSILHKNR LRNQVVHVPL EAYDSSLPLI KAILTAAIVD ADRIAVGLEE
     GLYVIEVTRD VIVRAADCKK VHQIELAPRE KIVILLCGRN HHVHLYPWSS LDGAEGSFDI
     KLPETKGCQL MATATLKRNS GTCLFVAVKR LILCYEIQRT KPFHRKFNEI VAPGSVQCLA
     VLRDRLCVGY PSGFCLLSIQ GDGQPLNLVN PNDPSLAFLS QQSFDALCAV ELESEEYLLC
     FSHMGLYVDP QGRRARAQEL MWPAAPVACS CSPTHVTVYS EYGVDVFDVR TMEWVQTIGL
     RRIRPLNSEG TLNLLNCEPP RLIYFKSKFS GAVLNVPDTS DNSKKQMLRT RSKRRFVFKV
     PEEERLQQRR EMLRDPELRS KMISNPTNFN HVAHMGPGDG MQVLMDLPLS AVPPSQEERP
     GPAPTNLARQ PPSRNKPYIS WPSSGGSEPS VTVPLRSMSD PDQDFDKEPD SDSTKHSTPS
     NSSNPSGPPS PNSPHRSQLP LEGLEQPACD T
//
